RNAi-mediated gene silencing in cancer therapy

Expert Opinion on Biological Therapy

Volumn 12, Issue 11, 2012, Pages 1495-1504

  Yang, Wei Qiong ^a   Zhang, Yi ^a  

^a SOOCHOW UNIVERSITY   (China)

Author keywords

Cancer therapy; Cell death; Cell survival; RNAi

Indexed keywords

8 [4 (1 AMINOCYCLOBUTYL)PHENYL] 9 PHENYL 1,2,4 TRIAZOLO[3,4 F][1,6]NAPHTHYRIDIN 3(2H) ONE; BRCA1 PROTEIN; CISPLATIN; CYCLIN E; DEOXYGLUCOSE; DOXORUBICIN; ELONGATION FACTOR 2 KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETOPOSIDE; HEAT SHOCK PROTEIN 27; HERMES ANTIGEN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MAMMALIAN TARGET OF RAPAMYCIN; MITOMYCIN C; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN GLUTAMINE GAMMA GLUTAMYLTRANSFERASE 2; PROTEIN KINASE B; RAPAMYCIN; SHORT HAIRPIN RNA; SMALL INTERFERING RNA; STAT PROTEIN; VASCULOTROPIN C;

ADENO ASSOCIATED VIRUS; ANGIOGENESIS; APOPTOSIS; AUTOPHAGY; CANCER THERAPY; CARCINOMA CELL; CELL CYCLE PROGRESSION; CELL DEATH; CELL PROLIFERATION; DNA METHYLATION; ENERGY METABOLISM; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENE THERAPY; HELA CELL; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE; PAPILLOMAVIRUS INFECTION; PROTEIN EXPRESSION; REVIEW; RNA INTERFERENCE; STOMACH CARCINOMA; ANIMAL; GENETICS; NEOPLASMS; PHYSIOLOGY; PROCEDURES; TRENDS;

ANIMALS; GENE SILENCING; GENETIC THERAPY; HUMANS; NEOPLASMS; RNA INTERFERENCE;

EID: 84867325735     PISSN: 14712598     EISSN: None     Source Type: Journal    
DOI: 10.1517/14712598.2012.712107     Document Type: Review

References (90)

1. Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease? Gene Ther 2006;13:496-502
2. Ambros V. The functions of animal microRNAs. Nature 2004;431:350-5
3. Nickels BE, Hochschild A. Regulation of RNA polymerase through the secondary channel. Cell 2004;118:281-4
4. Fire A, Xu S, Montgomery MK, et al. Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature 1998;391:806-11
5. Du T, Zamore PD. Microprimer: the biogenesis and function of microRNA. Development 2005;132:4645-52
6. Davis ME, Zuckerman JE, Choi CH, et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 2010;464:1067-70
7. Hammond SM, Bernstein E, Beach D, Hannon GJ. An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells. Nature 2000;404:293-6
8. Bernstein E, Caudy AA, Hammond SM, Hannon GJ. Role for a bidentate ribonuclease in the initiation step of RNA interference. Nature 2001;409:363-6
9. Tan FL, Yin JQ. Application of RNAi to cancer research and therapy. Front Biosci 2005;10:1946-60
10. Stevenson M. Therapeutic potential of RNA interference. N Engl J Med 2004;351:1772-7
11. Dykxhoorn DM, Chowdhury D, Lieberman J. RNA interference and cancer: endogenous pathways and therapeutic approaches. Adv Exp Med Biol 2008;615:299-329
12. Angaji SA, Hedayati SS, Poor RH, et al. Application of RNA interference in treating human diseases. J Genet 2010;89:527-37
13. Bohnsack MT, Czaplinski K, Gorlich D. Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. RNA 2004;10:185-91
14. Brummelkamp TR, Bernards R, Agami R. Stable suppression of tumorigenicity by virus-mediated RNA interference. Cancer Cell 2002;2:243-7
15. Purow BW, Haque RM, Noel MW, et al. Expression of Notch-1 and its ligands, Delta-like-1 and Jagged-1, is critical for glioma cell survival and proliferation. Cancer Res 2005;65:2353-63
16. Yuan J, Yan R, Kramer A, et al. Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells. Oncogene 2004;23:5843-52
17. Xiao Z, Xue J, Sowin TJ, et al. A novel mechanism of checkpoint abrogation conferred by Chk1 downregulation. Oncogene 2005;24:1403-11
18. Takei Y, Kadomatsu K, Yuzawa Y, et al. A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res 2004;64:3365-70
19. Filleur S, Courtin A, Ait-Si-Ali S, et al. SiRNA-mediated inhibition of vascular endothelial growth factor severely limits tumor resistance to antiangiogenic thrombospondin-1 and slows tumor vascularization and growth. Cancer Res 2003;63:3919-22
20. Kilic N, Oliveira-Ferrer L, Wurmbach JH, et al. Pro-angiogenic signaling by the endothelial presence of CEACAM1. J Biol Chem 2005;280:2361-9
21. Yin Q, Flemington EK. siRNAs against the Epstein Barr virus latency replication factor, EBNA1, inhibit its function and growth of EBV-dependent tumor cells. Virology 2006;346:385-93
22. Jiang M, Milner J. Selective silencing of viral gene expression in HPV-positive human cervical carcinoma cells treated with siRNA, a primer of RNA interference. Oncogene 2002;21:6041-8
23. Duan Z, Brakora KA, Seiden MV. Inhibition of ABCB1 (MDR1) and ABCB4 (MDR3) expression by small interfering RNA and reversal of paclitaxel resistance in human ovarian cancer cells. Mol Cancer Ther 2004;3:833-8
24. journalWu H, Hait WN, Yang JM. Small interfering RNA-induced suppression of MDR1 (P-glycoprotein) restores sensitivity to multidrug-resistant cancer cells. Cancer Res 2003;63:1515-9.
25. Yague E, Higgins CF, Raguz S. Complete reversal of multidrug resistance by stable expression of small interfering RNAs targeting MDR1. Gene Ther 2004;11:1170-4
26. Peng Z, Xiao Z, Wang Y, et al. Reversal of P-glycoprotein-mediated multidrug resistance with small interference RNA (siRNA) in leukemia cells. Cancer Gene Ther 2004;11:707-12
27. Chang IY, Kim MH, Kim HB, et al. Small interfering RNA-induced suppression of ERCC1 enhances sensitivity of human cancer cells to cisplatin. Biochem Biophys Res Commun 2005;327:225-33
28. Dykxhoorn DM, Lieberman J. The silent revolution: RNA interference as basic biology, research tool, and therapeutic. Annu Rev Med 2005;56:401-23
29. Dykxhoorn DM, Palliser D, Lieberman J. The silent treatment: siRNAs as small molecule drugs. Gene Ther 2006;13:541-52
30. Elbashir SM, Lendeckel W, Tuschl T. RNA interference is mediated by 21- and 22-nucleotide RNAs. Genes Dev 2001;15:188-200
31. Weinberg MS, Barichievy S, Schaffer L, et al. An RNA targeted to the HIV-1 LTR promoter modulates indiscriminate off-target gene activation. Nucleic Acids Res 2007;35:7303-12
32. McNamara JO II, Andrechek ER,Wang Y, et al. Cell type-specific delivery of siRNAs with aptamer-siRNA chimeras. Nat Biotechnol 2006;24:1005-15
33. Dassie JP, Liu XY, Thomas GS, et al. Systemic administration of optimized aptamer-siRNA chimeras promotes regression of PSMA-expressing tumors. Nat Biotechnol 2009;27:839-49
34. Wu Y, Wang W, Chen Y, et al. The investigation of polymer-siRNA nanoparticle for gene therapy of gastric cancer in vitro. Int J Nanomedicine 2010;5:129-36
35. Guo B, Zhang Y, Luo G, et al. Lentivirus-mediated small interfering RNA targeting VEGF-C inhibited tumor lymphangiogenesis and growth in breast carcinoma. Anat Rec (Hoboken) 2009;292:633-9
36. Michelfelder S, Trepel M. Adeno-associated viral vectors and their redirection to cell-type specific receptors. Adv Genet 2009;67:29-60
37. Nayak S, Herzog RW. Progress and prospects: immune responses to viral vectors. Gene Ther 2010;17:295-304
38. Poeck H, Besch R, Maihoefer C, et al. 5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma. Nat Med 2008;14:1256-63
39. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell 2008;132:27-42
40. Mathew R, Karantza-Wadsworth V, White E. Role of autophagy in cancer. Nat Rev Cancer 2007;7:961-7
41. Abedin MJ, Wang D, McDonnell MA, et al. Autophagy delays apoptotic death in breast cancer cells following DNA damage. Cell Death Differ 2007;14:500-10
42. Carew JS, Nawrocki ST, Kahue CN, et al. Targeting autophagy augments the anticancer activity of the histone deacetylase inhibitor SAHA to overcome Bcr-Abl-mediated drug resistance. Blood 2007;110:313-22
43. Morselli E, Galluzzi L, Kepp O, et al. Anti- and pro-tumor functions of autophagy. Biochim Biophys Acta 2009;1793:1524-32
44. Dalby KN, Tekedereli I, Lopez-Berestein G, Ozpolat B. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy 2010;6:322-9
45. Apel A, Herr I, Schwarz H, et al. Blocked autophagy sensitizes resistant carcinoma cells to radiation therapy. Cancer Res 2008;68:1485-94
46. Wu H, Zhu H, Liu DX, et al. Silencing of elongation factor-2 kinase potentiates the effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer Res 2009;69:2453-60
47. Cheng Y, Ren X, Zhang Y, et al. eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206. Cancer Res 2011;71:2654-63
48. Tang D, Kang R, Cheh CW, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. Oncogene 2010;29:5299-310
49. Tang D, Kang R, Livesey KM, et al. Endogenous HMGB1 regulates autophagy. J Cell Biol 2010;190:881-92
50. Niu TK, Cheng Y, Ren X, Yang JM. Interaction of Beclin 1 with survivin regulates sensitivity of human glioma cells to TRAIL-induced apoptosis. FEBS Lett 2010;584:3519-24
51. Zhang Y, Cheng Y, Ren X, et al. NAC1 modulates sensitivity of ovarian cancer cells to cisplatin by altering the HMGB1-mediated autophagic response. Oncogene 2012;31:1055-64
52. Ai Z, Yin L, Zhou X, et al. Inhibition of survivin reduces cell proliferation and induces apoptosis in human endometrial cancer. Cancer 2006;107:746-56
53. Zhen HN, Li LW, Zhang W, et al. Short hairpin RNA targeting survivin inhibits growth and angiogenesis of glioma U251 cells. Int J Oncol 2007;31:1111-17
54. Yamaguchi Y, Shiraki K, Fuke H, et al. Targeting of X-linked inhibitor of apoptosis protein or survivin by short interfering RNAs sensitize hepatoma cells to TNF-related apoptosis-inducing ligand- and chemotherapeutic agent-induced cell death. Oncol Rep 2005;14:1311-16
55. Yonesaka K, Tamura K, Kurata T, et al. Small interfering RNA targeting survivin sensitizes lung cancer cell with mutant p53 to adriamycin. Int J Cancer 2006;118:812-20
56. Kappler M, Taubert H, Bartel F, et al. Radiosensitization, after a combined treatment of survivin siRNA and irradiation, is correlated with the activation of caspases 3 and 7 in a wt-p53 sarcoma cell line, but not in a mt-p53 sarcoma cell line. Oncol Rep 2005;13:167-72
57. Taniai M, Grambihler A, Higuchi H, et al. Mcl-1 mediates tumor necrosis factor-related apoptosis-inducing ligand resistance in human cholangiocarcinoma cells. Cancer Res 2004;64:3517-24
58. Akagi H, Higuchi H, Sumimoto H, et al. Suppression of myeloid cell leukemia-1 (Mcl-1) enhances. chemotherapy-associated apoptosis in gastric cancer cells. Gastric Cancer 2012 Apr 24. [Epub ahead of print] DOI: 10.1007/s10120-012-0153-6
59. Zhang Y, Zhang JW, Lv GY, et al. Effects of STAT3 gene silencing and rapamycin on apoptosis in hepatocarcinoma cells. Int J Med Sci 2012;9:216-24
60. Zhang L, Zhao Z, Feng Z, et al. RNA interference-mediated silencing of Stat 5 induces apoptosis and growth suppression of hepatocellular carcinoma cells. Neoplasma 2012;59:302-9
61. Li K, Lin SY, Brunicardi FC, Seu P. Use of RNA interference to target cyclin E-overexpressing hepatocellular carcinoma. Cancer Res 2003;63:3593-7
62. Hata T, Furukawa T, Sunamura M, et al. RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells. Cancer Res 2005;65:2899-905
63. Duxbury MS, Ito H, Zinner MJ, et al. Focal adhesion kinase gene silencing promotes anoikis and suppresses metastasis of human pancreatic adenocarcinoma cells. Surgery 2004;135:555-62
64. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011;144:646-74
65. Peng Q, Zhou Q, Zhou J, et al. Stable RNA interference of hexokinase II gene inhibits human colon cancer LoVo cell growth in vitro and in vivo. Cancer Biol Ther 2008;7:1128-35
66. Guo W, Zhang Y, Chen T, et al. Efficacy of RNAi targeting of pyruvate kinase M2 combined with cisplatin in a lung cancer model. J Cancer Res Clin Oncol 2011;137:65-72
67. Le A, Cooper CR, Gouw AM, et al. Inhibition of lactate dehydrogenase A induces oxidative stress and inhibits tumor progression. Proc Natl Acad Sci USA 2010;107:2037-42
68. Langbein S, Zerilli M, Zur Hausen A, et al. Expression of transketolase TKTL1 predicts colon and urothelial cancer patient survival: Warburg effect reinterpreted. Br J Cancer 2006;94:578-85
69. Zhang S, Yue JX, Yang JH, et al. Overexpression of transketolase protein TKTL1 is associated with occurrence and progression in nasopharyngeal carcinoma: a potential therapeutic target in nasopharyngeal carcinoma. Cancer Biol Ther 2008;7:517-22
70. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab 2006;3:177-85
71. Wise DR, DeBerardinis RJ, Mancuso A, et al. Myc regulates a transcriptional program that stimulates mitochondrial glutaminolysis and leads to glutamine addiction. Proc Natl Acad Sci USA 2008;105:18782-7
72. Bartholomeusz C, Gonzalez-Angulo AM. Targeting the PI3K signaling pathway in cancer therapy. Expert Opin Ther Targets 2012;16:121-30
73. Suzuki S, Tanaka T, Poyurovsky MV, et al. Phosphate-activated glutaminase (GLS2), a p53-inducible regulator of glutamine metabolism and reactive oxygen species. Proc Natl Acad Sci USA 2010;107:7461-6
74. Hayflick L, Moorhead PS. The serial cultivation of human diploid cell strains. Exp Cell Res 1961;25:585-621
75. Campisi J, d'Adda di Fagagna F. Cellular senescence: when bad things happen to good cells. Nat Rev Mol Cell Biol 2007;8:729-40
76. Michaloglou C, Vredeveld LC, Soengas MS, et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005;436:720-4
77. Courtois-Cox S, Jones SL, Cichowski K. Many roads lead to oncogene-induced senescence. Oncogene 2008;27:2801-9
78. Collado M, Blasco MA, Serrano M. Cellular senescence in cancer and aging. Cell 2007;130:223-33
79. Qian X, Cheng J, Chen A, et al. Long-term effects of short hairpin RNA-targeted human telomerase reverse transcriptase on suppression of SGC-7901 cell proliferation by inhibition of telomerase activity. Oncol Rep 2008;19:575-81
80. Liu X, Huang H, Wang J, et al. Dendrimers-delivered short hairpin RNA targeting hTERT inhibits oral cancer cell growth in vitro and in vivo. Biochem Pharmacol 2011;82:17-23
81. Meng L, Hunt C, Yaglom JA, et al. Heat shock protein Hsp72 plays an essential role in Her2-induced mammary tumorigenesis. Oncogene 2011;30:2836-45
82. Sturla LM, Zinn PO, Ng K, et al. Src homology domain-containing phosphatase 2 suppresses cellular senescence in glioblastoma. Br J Cancer 2011;105:1235-43
83. Zhang Y, Yang JM. The impact of cellular senescence in cancer therapy: is it true or not? Acta Pharmacol Sin 2011;32:1199-207
84. Putral LN, Bywater MJ, Gu W, et al. RNA interference against human papillomavirus oncogenes in cervical cancer cells results in increased sensitivity to cisplatin. Mol Pharmacol 2005;68:1311-19
85. Santarosa M, Del Col L, Tonin E, et al. Premature senescence is a major response to DNA cross-linking agents in BRCA1-defective cells: implication for tailored treatments of BRCA1 mutation carriers. Mol Cancer Ther 2009;8:844-54
86. Soutschek J, Akinc A, Bramlage B, et al. Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs. Nature 2004;432:173-8
87. Song E, Zhu P, Lee SK, et al. Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors. Nat Biotechnol 2005;23:709-17
88. Medarova Z, Pham W, Farrar C, et al. In vivo imaging of siRNA delivery and silencing in tumors. Nat Med 2007;13:372-7
89. Judge AD, Sood V, Shaw JR, et al. Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA. Nat Biotechnol 2005;23:457-62
90. Song E, Lee SK, Dykxhoorn DM, et al. Sustained small interfering RNA-mediated human immunodeficiency virus type 1 inhibition in primary macrophages. J Virol 2003;77:7174-81